PATENT CLAIM ANALYSIS

Application Number: 15963510
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2019-03
Patent Classification: ["514", "04400A"]

Abstract:
The present invention relates to methods of treating a condition associated with mTORC1 hyperactivation or TSC2-deficient cancer, the method comprising administering to a subject having the cancer a pharmaceutically-effective amount of a poly(ADP-ribose) polymerase 1 (PARP1) inhibitor. In some embodiments, the condition associated with mTORC1 hyperactivation is tuberous sclerosis complex (TSC). In some embodiments, the condition associated with mTORC1 hyperactivation is lymphangioleiomyomatosis (LAM). In some embodiments, the condition associated with mTORC1 hyperactivation is TSC2-deficient cancer.

Claim (Index 10):
The method of  claim 1 , wherein the administering is systemic.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 91.0
- Lexical Diversity: 2.04444
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15305883', '14771817', '12989529', '14853468', '14990651']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7797004024267242
- 35 USC 102 Novelty (BERT): 0.6575515008851398
- Combined Prediction Score: 0.7674855122725658
- Mean Citation Score: 375.462228
- Max Citation Score: 728.1462
- Similarity Product: 587.5276888784766

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test